Fuzeon With Needle-Free Delivery To Be Resubmitted In Latter Half Of 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Trimeris expects to submit a response to FDA in the second half of 2006 following receipt of an "approvable" letter for use of its fusion inhibitor Fuzeon with a needle-free injection system